This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Endo Pharmaceuticals Inc.
Endo Pharmaceuticals Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 1997, the company has established itself as a leader in pain management and urology, focusing on innovative therapies that address unmet medical needs. With a strong presence across North America, Endo is dedicated to developing and commercialising a diverse portfolio of products, including prescription medications and medical devices. Endo's core offerings, such as its advanced pain management solutions and specialty pharmaceuticals, are distinguished by their commitment to quality and efficacy. The company has achieved significant milestones, including the successful launch of several key products that have positively impacted patient care. As a trusted name in the industry, Endo Pharmaceuticals continues to enhance its market position through ongoing research and development, striving to improve the lives of patients worldwide.
DitchCarbon Score
How does Endo Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Endo Pharmaceuticals Inc.'s score of 33 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Endo Pharmaceuticals Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years, as indicated by the absence of emissions figures. The company is a current subsidiary of Endo Inc., which may influence its climate commitments and reporting practices. Endo Pharmaceuticals has not publicly disclosed any reduction targets or initiatives related to carbon emissions, nor does it appear to have set Science-Based Targets Initiative (SBTi) targets. This lack of specific commitments may reflect broader industry trends where pharmaceutical companies are increasingly scrutinised for their environmental impact. As a subsidiary, Endo Pharmaceuticals may inherit climate-related data and initiatives from its parent company, Endo Inc., which is responsible for reporting emissions data and performance metrics. However, without specific figures or commitments from Endo Pharmaceuticals itself, it is challenging to assess its individual climate impact or progress. In summary, while Endo Pharmaceuticals Inc. is part of a larger corporate structure that may have climate initiatives, it currently lacks publicly available emissions data and defined reduction targets.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 27,475,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 37,395,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Endo Pharmaceuticals Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
